Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 2Lennox Gastaut Syndrome 2Epilepsies, Myoclonic 2Seizures 1Liver Cirrhosis 1

Interventions

pembrolizumab 166Carboplatin 132Cisplatin 81Paclitaxel 78Gemcitabine 77Pemetrexed 72Bevacizumab 63Docetaxel 54Fluorouracil 49Oxaliplatin 48Dexamethasone 46durvalumab 43atezolizumab 39Leucovorin 39130-nm albumin-bound paclitaxel 39Capecitabine 37Cetuximab 36Rituximab 35Nivolumab 35Fulvestrant 35Cyclophosphamide 34Injections 31venetoclax 29Prednisone 28Lenalidomide 28enzalutamide 27pomalidomide 25Letrozole 25Irinotecan 25daratumumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Cannabidiol × 30 days × Clear all
NCT05485831 2026-06-03

EpiTALY

Jazz Pharmaceuticals

Active not recruiting
111 enrolled

Epilepsies, Myoclonic, Seizures, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT05044819 2026-06-01

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Jazz Pharmaceuticals

Phase 4 Active not recruiting
154 enrolled

Epilepsies, Myoclonic, Liver Cirrhosis, Tuberous Sclerosis, Lennox Gastaut Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡